Serious adverse events
| Patient . | Days post–first VST infusion . | Event . |
|---|---|---|
| 1 | 108 | Rhinovirus RTI |
| 180 | Escherichia coli UTI | |
| 5 | 354 | Respiratory syncytial virus RTI |
| 6 | 314 | Streptococcus pneumoniae pneumonia/sepsis |
| 7 | 251 | RTI (no organism identified) |
| 9 | 45 | RTI (no organism identified) |
| 54 | Rhinovirus and Influenza A(H3) RTI* | |
| 54 | Pseudomonas putida pneumonia/sepsis† | |
| 56 | Enterococcus faecium pneumonia/sepsis† | |
| 11 | 8 | Disseminated ADV infection† (urine, blood, stool, GIT) |
| 21 | Grade IV gut GVHD with hemorrhage† | |
| 12 | 29 | Stevens-Johnson syndrome (skin, ocular, oral, and genital mucosa) |
| 41 | Posterior reversible encephalopathy syndrome | |
| 13 | 9 | Disseminated Toxoplasma gondii† (cerebral, CSF, blood, and BMAT) |
| 14 | 50 | Serratia marcescens bacteremia (line-related) |
| 15 | 190 | Presumed Pneumocystis jirovecii pneumonia† |
| 16 | 19 | Respiratory failure due to fluid overload |
| 32 | Posterior reversible encephalopathy syndrome | |
| 17 | 23 | Human metapneumovirus RTI |
| 31 | Enterococcus faecium pneumonia/empyema† | |
| 18 | 1, 16 | Pseudomonas aeruginosa RTI |
| 16 | Rhinovirus RTI | |
| 19 | 80 | Rotavirus diarrhea |
| 20 | 126 | RLL pneumonia, no organism identified |
| 23 | 291 | Enterococcus faecalis and Enterobacter cloacae UTI |
| 24 | 7 | Respiratory syncytial virus RTI |
| 24 | Orbital cellulitis, no organism identified | |
| 52 | Pseudomonas aeruginosa bacteremia | |
| 53 | Cerebral EBV PTLD† | |
| 65 | Respiratory failure, Candida sp., Corynebacterium sp., CMV PCR+, EBV PCR+ (BAL)† | |
| 26 | 11 | Febrile, no organism identified |
| Patient . | Days post–first VST infusion . | Event . |
|---|---|---|
| 1 | 108 | Rhinovirus RTI |
| 180 | Escherichia coli UTI | |
| 5 | 354 | Respiratory syncytial virus RTI |
| 6 | 314 | Streptococcus pneumoniae pneumonia/sepsis |
| 7 | 251 | RTI (no organism identified) |
| 9 | 45 | RTI (no organism identified) |
| 54 | Rhinovirus and Influenza A(H3) RTI* | |
| 54 | Pseudomonas putida pneumonia/sepsis† | |
| 56 | Enterococcus faecium pneumonia/sepsis† | |
| 11 | 8 | Disseminated ADV infection† (urine, blood, stool, GIT) |
| 21 | Grade IV gut GVHD with hemorrhage† | |
| 12 | 29 | Stevens-Johnson syndrome (skin, ocular, oral, and genital mucosa) |
| 41 | Posterior reversible encephalopathy syndrome | |
| 13 | 9 | Disseminated Toxoplasma gondii† (cerebral, CSF, blood, and BMAT) |
| 14 | 50 | Serratia marcescens bacteremia (line-related) |
| 15 | 190 | Presumed Pneumocystis jirovecii pneumonia† |
| 16 | 19 | Respiratory failure due to fluid overload |
| 32 | Posterior reversible encephalopathy syndrome | |
| 17 | 23 | Human metapneumovirus RTI |
| 31 | Enterococcus faecium pneumonia/empyema† | |
| 18 | 1, 16 | Pseudomonas aeruginosa RTI |
| 16 | Rhinovirus RTI | |
| 19 | 80 | Rotavirus diarrhea |
| 20 | 126 | RLL pneumonia, no organism identified |
| 23 | 291 | Enterococcus faecalis and Enterobacter cloacae UTI |
| 24 | 7 | Respiratory syncytial virus RTI |
| 24 | Orbital cellulitis, no organism identified | |
| 52 | Pseudomonas aeruginosa bacteremia | |
| 53 | Cerebral EBV PTLD† | |
| 65 | Respiratory failure, Candida sp., Corynebacterium sp., CMV PCR+, EBV PCR+ (BAL)† | |
| 26 | 11 | Febrile, no organism identified |
BAL, bronchoalveolar lavage; BMAT, bone marrow aspirate and trephine; CSF, cerebral spinal fluid; GIT, gastrointestinal; RLL, right lower lobe; RTI, respiratory tract infection; sp., species; UTI, urinary tract infection.
*Rhinovirus and Influenza A(H3) RTI was initially diagnosed on day 34 post–VST infusion.
Contributed to death.